Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269876 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HTTCYP19A1MAPTCYP1A2 | |
| SCHEMBL8085829 | 0.76 | ALDH1A1 (0.43) | ALDH1A1LMNAHTTCYP19A1MAPT | |
| SCHEMBL8085548 | 0.76 | ALDH1A1 (0.43) | VCAM1ALDH1A1LMNAHTTCYP19A1 | |
| SCHEMBL159009 | 0.72 | MAPT (0.53) | VCAM1ALDH1A1HTTMAPTGRIA1 | |
| SCHEMBL626564 | 0.71 | MAPT (0.51) | VCAM1ALDH1A1HTTMAPTGRIA1 | |
| SCHEMBL30456072 | 0.71 | MAPT (0.51) | VCAM1ALDH1A1HTTMAPTGRIA1 | |
| Water SCHEMBL30261034 | 0.71 | MAPT (0.51) | VCAM1ALDH1A1HTTMAPTGRIA1 | |
| SCHEMBL2964049 | 0.69 | XDH (0.77) | VCAM1XDHALDH1A1LMNAGAA | |
| SCHEMBL11871225 | 0.69 | VCAM1 (0.65) | VCAM1XDHALDH1A1LMNAGAA | |
| SCHEMBL11860384 | 0.69 | VCAM1 (0.61) | VCAM1XDHALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | THE BROAD INSTITUTE, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12227578-B2 | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action | THE BROAD INSTITUTE, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2024216255-A1 | DOUBLE CORE-SHELL NANODISC SYNTHESIS AND APPLICATION TO MAGNETOELECTRIC BIO-SIGNALING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-115927476-A | Method for reprogramming fibroblasts into autonomic ganglion organoids | 向孟清 | 2023-04-07 | — | — | CN | disclosed |
| US-20210040442-A1 | MODULATION OF EPITHELIAL CELL DIFFERENTIATION, MAINTENANCE AND/OR FUNCTION THROUGH T CELL ACTION, AND MARKERS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-11 | — | — | US | disclosed |
| US-20190263912-A1 | MODULATION OF INTESTINAL EPITHELIAL CELL DIFFERENTIATION, MAINTENANCE AND/OR FUNCTION THROUGH T CELL ACTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | GPR3, GALR3, NR4A3 | VCAM1 632/4885XDH 3538/4885ALDH1A1 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.